Zydus Lifesciences is launching a proof-of-concept Phase 2a clinical trial to evaluate the safety and efficacy of its oral…
Articles by Steve Bryson, PhD
Pfizer has voluntarily withdrawn Oxbryta (voxelotor), a conditionally approved oral therapy for sickle cell disease (SCD), from worldwide…
The American Institutes for Research (AIR) has been awarded a $28 million federal contract to help make cell and gene…
The U.S. Food and Drug Administration (FDA) gave the greenlight for Iomab-ACT, a potentially less toxic conditioning regimen, to…
Hydroxyurea does not reduce ovarian reserve, or the quantity and quality of eggs in the ovaries, in girls and…
All 18 adults with severe sickle cell disease (SCD) treated with the gene-editing therapy renizgamglogene autogedtemcel — known as…
Nearly all people with sickle cell disease (SCD) treated with the U.S.-approved gene-editing therapy Casgevy (exagamglogene autotemcel) were…
Short-term exposure to air pollutants may be associated with a higher risk of hospitalization among children with sickle cell…
A nurse training program at the University of Tennessee Health Science Center (UTHSC) is expanding to train more nurses…
People with sickle cell disease (SCD) or sickle cell trait (SCT) face an increased risk of hospitalization and mortality…